Traditional Chinese medicine compound granules as well as preparation method and application thereof
Patent Information
- Application Number
- CN202411317035.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-20
- Publication Date
- 2024-11-26
Smart Images

Figure CN119015349A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of traditional Chinese medicine, and more specifically, relates to a traditional Chinese medicine compound granule and a preparation method and application thereof. Background Art
[0002] Allergic rhinitis (AR) is also called allergic rhinitis. Common symptoms mainly include nasal itching, sneezing, runny nose, nasal congestion, etc. AR has always been a global concern. In recent years, the prevalence of AR has shown a clear upward trend. At present, about 190 million adults and 220 million children suffer from allergic rhinitis, and the global probability of suffering from AR is as high as 10%-40%. Relevant studies have shown that air pollution can lead to an increase in the prevalence of AR and the occurrence and deterioration of airborne pollen-induced AR. Among them, the Environmental Comprehensive Quality Index Score (ECQI) can evaluate the outdoor environment and indoor air quality of the home. Its high score has been proven to be highly correlated with environmental factors and the risk of asthma and allergies in children, which has seriously affected people's lives and health. Therefore, the means to treat AR are urgent.
[0003] Traditional Chinese medicine is a traditional treatment method. It focuses on prevention before illness occurs and treatment based on syndrome differentiation. It has the advantages of safe and reliable efficacy, so more and more people are willing to use traditional Chinese medicine for treatment. For AR, traditional Chinese medicine treatment mainly includes oral administration of Chinese medicine, acupuncture and medicine combination, and integration of Chinese and Western medicine. However, in any case, treatment methods, from Chinese medicine to Western medicine, oral to surgery, will have certain side effects, poor compliance, and high treatment costs. Summary of the invention
[0004] The purpose of the present invention is to provide a Chinese medicine compound granule and its preparation method and application in view of the deficiencies of the prior art. The present invention uses the Chinese medicine compound granule as a preparation for the treatment of allergic rhinitis and adopts a heating inhalation administration method, which is simple to operate, low in cost and good in compliance.
[0005] In order to achieve the above object, the first aspect of the present invention provides a Chinese medicine compound granule, wherein the Chinese medicine compound granule comprises a Chinese herbal medicine mixture, peppermint essential oil and a binder;
[0006] The Chinese herbal medicine mixture includes Xanthium sibiricum, Magnolia officinalis, Angelica dahurica, Houttuynia cordata and Tangerine peel.
[0007] According to the present invention, preferably, based on the total weight of the Chinese medicine compound granules, the Chinese medicine compound granules include 67.5-78.5% of the Chinese herbal medicine mixture, 1.5-2.5% of peppermint essential oil and 20-30% of a binder.
[0008] According to the present invention, preferably, the mass ratio of Xanthium sibiricum, Flos Magnolias, Angelica dahurica, Houttuynia cordata and Pericarpium Citri Reticulatae is (1.5-2.5): (1.5-2.5): (2.5-3.5): (3.5-4.5): (3.5-4.5).
[0009] According to the present invention, preferably, the binder is at least one of glycerol, honey and CMC-Na (sodium carboxymethylcellulose) solution.
[0010] The second aspect of the present invention provides a method for preparing the Chinese medicine compound granules, the method comprising the following steps:
[0011] S1: uniformly mixing the peppermint essential oil and the adhesive to obtain an essential oil mixture;
[0012] S2: uniformly mixing the Xanthium sibiricum, Magnolia officinalis, Angelica dahurica, Houttuynia cordata and Citrus reticulatae, and sequentially crushing and sieving to obtain a Chinese herbal medicine mixture;
[0013] S3: The essential oil mixture and the Chinese herbal medicine mixture are uniformly mixed (to obtain a mixture that can be lightly grasped and dispersed when touched), and then mixed and granulated, screened once, dried, cooled and screened twice to obtain the Chinese herbal compound granules.
[0014] In step S1 of the present invention, the peppermint essential oil and the adhesive are firstly uniformly mixed, the purpose of which is to prevent the peppermint essential oil from being mixed unevenly.
[0015] According to the present invention, preferably, in step S2, the mesh size of the sieve is 80-120 meshes. According to the present invention, preferably, in step S3:
[0016] The mesh number of the first screening is 22-26 meshes, preferably, the first screening uses a No. 2 sieve; the mesh number of the second screening is 12-16 meshes, preferably, the second screening uses a No. 16 sieve;
[0017] The drying temperature is 55-65°C and the drying time is 7.5-9 minutes.
[0018] In the present invention, the drying conditions of the wet granulation of the present invention are also important conditions for determining the formability of the particles. In order to prevent the loss of volatile components in the Chinese medicine compound granules due to excessive drying time, the drying conditions are preferably heated at 60° C. for 8 minutes. By observing the appearance, particles with uniform particle size, uniform dark brown color, and compactness can be obtained. Figure 1 shown.
[0019] The present invention compares the particle sizes of three batches of Chinese medicine compound granules prepared within 20 days and the mass changes before and after drying, and it is found that the three batches of Chinese medicine compound granules cannot pass through the No. 1 sieve and can pass through the No. 2 sieve (particle size) do not exceed 15% of the total amount, and the mass reduction (loss on drying) does not exceed 10%, which meets the requirements, as shown in Table 1.
[0020] Table 1
[0021] Granule batch number Particle size / % Loss on drying / % 1 6.92 5.67 2 5.44 6.42 3 8.48 7.46
[0022] The third aspect of the present invention provides the use of the Chinese medicine compound granules as a medicine for preparing a medicine for treating allergic rhinitis.
[0023] According to the present invention, preferably, the drug for treating allergic rhinitis is administered by heated inhalation.
[0024] According to the present invention, preferably, the heating temperature is 250-270°C.
[0025] The beneficial effects of the technical solution of the present invention are as follows:
[0026] The present invention uses the Chinese medicine compound granules as the preparation of the drug for treating allergic rhinitis and adopts the heating inhalation administration method, so that the volatile components released can directly contact the nasal mucosa. Since the nasal mucosa has a large area and abundant blood vessels and blood flow, the drug administered through the nose can be quickly absorbed, the patient compliance is good, and the liver and kidney toxicity can be reduced.
[0027] The invention has the advantages of simple operation, low cost and good compliance.
[0028] Other features and advantages of the present invention will be described in detail in the following detailed description. BRIEF DESCRIPTION OF THE DRAWINGS
[0029] The above and other objects, features and advantages of the present invention will become more apparent through a more detailed description of exemplary embodiments of the present invention in conjunction with the accompanying drawings, wherein like reference numerals generally represent like components throughout the exemplary embodiments of the present invention.
[0030] Figure 1 A physical picture of a Chinese medicine compound granule provided in Example 1 of the present invention is shown.
[0031] Figure 2 The diagram of the experimental device for conducting an inhalation administration experiment (in vivo animal experiment) on the Chinese medicine compound granules of Example 1 in the test example of the present invention is shown.
[0032] Figure 3The AR mouse modeling and drug administration flow chart of the test example of the present invention is shown (Sensitization-sensitization, alum-aluminum hydroxide PBS adjuvant, treatment-treatment, dose-dose, inhai-inhalation, challenge-challenge, per-each, nasal cavity-nasal cavity, sacrifice-sacrifice).
[0033] Figure 4A -C respectively show the body weight of mice in the test example of the present invention and the behavioral characteristics of allergic rhinitis induced by OVA (body weight-body weight, Days after Administration-body weight of mice in each group on the 22nd to 27th day, (Nasal Sneezing (number / 20minuters)-number of sneezing (within 20min), Nasal Rubbing (number / 20minuters)-number of scratching nose (within 20min), Figure 4A -C All values given are mean±SD (n=9). Compared with the control group, #P<0.05; ##P<0.01; ###P<0.001; compared with the model group (OVA), *P<0.05; **P<0.01; ***P<0.001).
[0034] Figures 5Ⅰ-Ⅸ respectively show the pathological changes of nasal mucosa and lung tissue of OVA-induced AR mice before and after administration in the test example of the present invention (nasal mucosa staining, Ⅰ: HE staining; Ⅱ: Giemsa staining; Ⅲ: PAS staining; Ⅳ: TB staining. Lung tissue staining, Ⅴ: HE staining. Ⅵ: nasal mucosal thickness (μm); Ⅶ: number of eosinophils; Ⅷ: number of goblet cells; Ⅸ: number of mast cells. A: control group (Control); B: model group (OVA); C: low-dose group (ZHW-L); D: medium-dose group (ZHW-M) ; E: high-dose group (ZHW-H); F: budesonide group (Budesonide). Note: In the section staining, the scale bar of nasal mucosa = 50μm, the scale bar of lung tissue = 100μm, the values represent mean±SD (n=9), compared with the control group, #P<0.05; ##P<0.01; ###P<0.001; compared with the model group, *P<0.05; **P<0.01; ***P<0.001. Mucosathickness-nasal mucosal thickness, Eosinophil number-eosinophil number, Goblet cell number-goblet cell number, Mast cell number-mast cell number).
[0035] Fig. 6A-B respectively show the effect of the Chinese medicine compound granules of the test example 1 of the present invention on the spleen index and thymus index of OVA-induced AR mice (Index of spleen-spleen index; Index of thymus-thymus index; Fig. 6A -B all values are mean±SD (n=9). Compared with the control group, #P<0.05; ##P<0.01; ###P<0.001; compared with the model group, *P<0.05; **P<0.01; ***P<0.001).
[0036] Fig. 7A -D respectively show the effect of the Chinese medicine compound granules of the test example 1 of the present invention on the number of peripheral leukocytes in OVA-induced AR mice (WBC-total white blood cells; Lymph-peripheral blood lymphocytes; Mon-monocytes; Gran-eosinophils; Fig. 7A -D The values given are mean±SD (n=9). Compared with the control group, #P<0.05; ##P<0.01; ###P<0.001; compared with the model group, *P<0.05; **P<0.01; ***P<0.001).
[0037] Fig. 8A -D respectively show the effect of the Chinese medicine compound granules of the test example 1 of the present invention on the serum of OVA-induced AR mice (IFN-γin serum-IFN-γ in serum, IL-4in serum-IL-4 in serum, Histamine in serum-HIS in serum, OVA-Specific lgE-serological specific marker of allergic rhinitis mice (OVA-slgE); Fig. 8A -D The values given are mean±SD (n=9). Compared with the control group, #P<0.05; ##P<0.01; ###P<0.001; compared with the model group, *P<0.05; **P<0.01; ***P<0.001).
[0038] Fig.9A -B respectively show the effect of the Chinese medicine compound granules of the test example 1 of the present invention on the NALF (nasal wash fluid) of OVA-induced AR mice ( Fig.9A -B all values are mean±SD (n=9). Compared with the control group, #P<0.05; ##P<0.01; ###P<0.001; compared with the model group, *P<0.05; **P<0.01; ***P<0.001).
[0039] Fig. 10A-B respectively show the effect of the Chinese medicine compound granules of the test example 1 of the present invention on the lung tissue (Lung) of OVA-induced AR mice ( Fig. 10A -B all values are mean±SD (n=9). Compared with the control group, #P<0.05; ##P<0.01; ###P<0.001; compared with the model group, *P<0.05; **P<0.01; ***P<0.001).
[0040] The following are the descriptions of the reference numerals:
[0041] 1 Heating plate, 2 Thick glass funnel, 3 Whole body exposure system, 4 Vacuum pump. DETAILED DESCRIPTION
[0042] The preferred embodiments of the present invention will be described in more detail below. Although the preferred embodiments of the present invention are described below, it should be understood that the present invention can be implemented in various forms and should not be limited by the embodiments set forth herein. On the contrary, these embodiments are provided to make the present invention more thorough and complete, and to fully convey the scope of the present invention to those skilled in the art.
[0043] Example 1
[0044] This embodiment provides a Chinese medicine compound granule. Based on the total weight of the Chinese medicine compound granule, the Chinese medicine compound granule comprises 73% of a Chinese herbal medicine mixture, 2% of peppermint essential oil and 25% of a binder glycerol.
[0045] The Chinese herbal medicine mixture comprises Xanthium sibiricum, Magnolia bud, Angelica dahurica, Houttuynia cordata and Tangerine peel, and the mass ratio of Xanthium sibiricum, Magnolia bud, Angelica dahurica, Houttuynia cordata and Tangerine peel is 2:2:3:4:4.
[0046] The preparation method of the above-mentioned Chinese medicine compound granules comprises the following steps:
[0047] S1: uniformly mixing the peppermint essential oil and the adhesive to obtain an essential oil mixture;
[0048] S2: uniformly mixing the Xanthium sibiricum, Magnolia officinalis, Angelica dahurica, Houttuynia cordata and Citrus reticulatae, and sequentially crushing and passing through a 100-mesh sieve to obtain a Chinese herbal medicine mixture;
[0049] S3: The essential oil mixture and the Chinese herbal medicine mixture are uniformly mixed to obtain a mixture that can be easily grasped and dispersed by touch, and the mixture is mixed and granulated in sequence, passed through a No. 2 sieve, dried, cooled and sieved through a No. 16 sieve to obtain the Chinese herbal compound granules, which are then bagged and sealed.
[0050] The drying temperature was 60°C and the drying time was 8 minutes.
[0051] Embodiment 2-9
[0052] The difference between Example 2-9 and Example 1 is that the drying conditions in step S3 are different. See Table 2 for details.
[0053] In the present invention, the drying conditions of the wet granulation of the present invention are also important conditions for determining the formability of the particles. The present invention examines 9 parts of Chinese medicine compound granules under different drying time and temperature conditions, and compares the water content of each group, as shown in Table 2. The present invention preferably uses the drying condition of heating at 60°C for 8 minutes to prevent the loss of volatile components in the Chinese medicine compound granules due to excessive drying time. Through the observation of appearance, the present invention obtains particles with uniform size, uniform dark brown color, and compact and not loose particles, such as Figure 1 shown.
[0054] Table 2
[0055] Drying temperature / ℃ Drying time / min Water content / % Example 2 40 6 21.3 Example 3 40 8 18.8 Example 4 40 10 15.2 Example 5 50 6 16.8 Example 6 50 8 14.2 Example 7 50 10 10.8 Example 8 60 6 8.4 Example 1 60 8 6.8 Example 9 60 10 3.5
[0056] Example 10
[0057] This example uses the Chinese medicine compound granules of Example 1 as a preparation for the treatment of allergic rhinitis. The treatment of allergic rhinitis is administered by heating inhalation, and the heating temperature is 260°C.
[0058] Examples 11-13
[0059] The difference between Examples 11-13 and Example 10 is only that the heating temperature is different.
[0060] The heating temperature in Example 11 was 180°C.
[0061] The heating temperature in Example 12 was 220°C.
[0062] The heating temperature in Example 13 is 300°C.
[0063] According to the GC-MS (gas chromatography-mass spectrometry) comparison of the volatile components in the traditional Chinese medicine compound granules at four different temperatures, as shown in Table 3 (only the characteristic substances of the compound granules are listed), it can be seen that:
[0064] The effective ingredients in the Chinese medicine compound granules at 260°C are as much as those at the other three temperatures, and the effective ingredients include linalool, menthol, eucalyptol, and pinoleol, which are ingredients with certain anti-inflammatory effects;
[0065] 180℃, the temperature may be too low to evaporate the volatile components;
[0066] 300℃, the temperature may be too high to destroy the active ingredients or release other toxic substances;
[0067] After comprehensive consideration, the present invention preferably selects 260°C as the optimum temperature for subsequent in vivo animal experiments. The relative percentages of the active ingredients in the Chinese medicine compound granules at 260°C are shown in Table 3 below.
[0068] Table 3
[0069]
[0070]
[0071] Note: “×” indicates that the substance was not detected in the Chinese medicine compound; “√” indicates that the substance was detected in the Chinese medicine compound
[0072] Test Case
[0073] In this test example, the Chinese medicine compound granules of Example 1 were subjected to an inhalation administration experiment in mice (in vivo animal experiment).
[0074] Experimental setup Figure 2 As shown, it consists of a heating plate, a thick glass funnel, a whole-body exposure system, and an aspiration pump.
[0075] The specific experimental operation methods include:
[0076] After KM female mice (Kunming mice) were raised normally for one week, they were randomly divided into six groups, with 9 mice in each group, corresponding to: low-dose group (ZHW-L), medium-dose group (ZHW-M), high-dose group (ZHW-H), control group (Control), model group (OVA), positive control group (Budesonide group);
[0077] According to the preliminary experiment, the present invention can draw the following conclusions: the modeling is carried out by the same method, and the success of the modeling is determined by observing the behavior of mice (sneezing and scratching the nose); the dosage is determined by comparing with the behavior of the model group (OVA), and it can be concluded that the Chinese medicine compound granules in Example 1 have a certain therapeutic effect when the dosage is about 0.5-2.0g, so the low-dose group (ZHW-L) is determined to be 0.5g, the medium-dose group (ZHW-M) is determined to be 1.0g, and the high-dose group (ZHW-H) is determined to be 2.0g. When the atomized inhalation dosage of the positive control group (budesonide group) is 1.0mg, there is an obvious relief effect, which is manifested in a significant reduction in the number of sneezing and scratching the nose, so the dosage of the positive control group (budesonide group) is determined to be 1.0mg each time.
[0078] like Figure 3As shown, the administration method was determined as follows: the entire experimental period was a total of 28 days. After one week of adaptive feeding, except for the control group, all other groups were intraperitoneally injected with 200 μl of 50 μg OVA (ovalbumin) and 1 mg aluminum hydroxide PBS adjuvant on days 0, 7, and 14 as basic sensitization. At the same time, the control group was intraperitoneally injected with an equal amount of PBS. From day 21 to day 27, at the same time every day for 7 consecutive days, 25 mg / ml OVA was injected into the nose with a 10 mL syringe for local sensitization. 20 μl was administered to each nostril on both sides of the mouse for stimulation. Note that any leakage during the nasal drip process must be replenished in time. At the same time, medication was given on days 15 to 27, using Figure 2 The drug delivery device was used, and blood was collected from the eyeball on the 28th day. After the model was established, the number of sneezing and runny nose of each group of mice was recorded in a blind manner 20 minutes after the nasal sensitization of the mice on the 21st, 25th, and 27th days, and compared with the model group (OVA). At the same time, the weight of each group of mice was recorded for 6 days from the 22nd to the 27th day, and the weight of each group was compared.
[0079] use Figure 2 The specific process of drug administration using the drug administration device is as follows: 9 mice in each group are placed in the whole body exposure system, and the temperature of the heating plate is set to 260°C. When the temperature rises to 260°C, turn on the vacuum pump first, and then place the drug under the thick glass funnel. Note that the glass funnel should completely cover the drug to prevent the volatile components from leaking out. After heating for 15 minutes, turn off the heating plate and continue to use the vacuum pump to keep it turned off for 5 minutes.
[0080] The experimental results are as follows:
[0081] like Figure 4A As shown, in this test example, the weight of mice in each group was recorded on days 22-27, a total of 6 days. Figure 4A As shown, there was no significant difference (P>0.05) among the mice in the control group (Control), model group (OVA), low-dose group (ZHW-L), medium-dose group (ZHW-M), high-dose group (ZHW-H) and positive control group (Budesonide group), indicating that the Chinese medicine compound granules in Example 1 had no toxicity to the body weight and food intake of mice.
[0082] like Figure 4B As shown in Figure 1-C, after the last local sensitization, the number of sneezing and nose scratching of the mice was recorded within 20 minutes to evaluate the effect of the Chinese medicine compound granules in Example 1 on the behavior of OVA-induced allergic rhinitis. Figure 4B-C shows that compared with the control group (Control), the number of sneezing and scratching symptoms in OVA-induced AR (model group (OVA)) mice increased significantly (P < 0.001). Compared with the model group (OVA), the number of sneezing and scratching symptoms in different doses of Chinese herbal compound granules groups decreased significantly (P < 0.05), among which the high-dose group (ZHW-H) showed significant differences compared with the model group (OVA) (P < 0.001). These results show that the inhalation administration of the Chinese herbal compound granules in Example 1 can effectively improve the symptoms of OVA-induced allergic rhinitis in vivo.
[0083] Figure 5Ⅰ is HE (Hematoxylin-eosin, eosin staining) staining of the nasal mucosa, showing that: compared with the control group (Figure 5Ⅰ-A), the model group (Figure 5Ⅰ-B) had obvious interstitial edema (as indicated by the blue arrow in the figure) and inflammatory cell infiltration, and the mucosal base was significantly thickened (Figure 5Ⅵ), which was significantly different from the control group (P < 0.01); and as shown in Figures 5Ⅰ-C, 5Ⅰ-D, 5Ⅰ-E, and 5Ⅵ, after the administration of the Chinese medicine compound granules of Example 1, interstitial edema and inflammatory cell infiltration were reduced, and the mucosal thickness was significantly reduced in a dose-dependent manner, among which the high-dose group was significantly different from the model group (P < 0.001).
[0084] Figure 5Ⅱ uses Giemsa staining to explore the infiltration of eosinophils in the nasal mucosa. As can be seen from Figure 5Ⅱ, inflammatory cells including eosinophils infiltrate (as indicated by the black arrows in Figure 5Ⅱ). At the same time, compared with the control group, the number of eosinophils in the model group increased significantly (Figure 5Ⅶ), with a significant difference (P < 0.01). After administration, the low-dose group, medium-dose group and high-dose group had significantly fewer eosinophils than the model group, all with significant differences (P < 0.01).
[0085] Figure 5Ⅲ uses PAS (Periodic acid-Schiff) staining to explore the changes in goblet cells in the nasal mucosa. As can be seen from Figure 5Ⅲ, the goblet cell hyperplasia in the model group (Figure 5Ⅲ-B) is significant compared with the control group (Figure 5Ⅲ-A) (as indicated by the black arrow in the figure), and there is a significant difference (P < 0.01) (Figure 5Ⅷ). After inhalation administration, goblet cell hyperplasia is reduced, and the high-dose group (Figure 5Ⅲ-E) is significantly different from the model group (Figure 5Ⅲ-B) (P < 0.01).
[0086] Figure 5Ⅳ uses toluidine blue (TB, Toluidine blue) staining to explore the infiltration of mast cells in the nasal mucosa. It can be seen from Figures 5Ⅳ and 5Ⅸ that the infiltration of mast cells in the model group is significant, and there is a significant difference compared with the control group (P < 0.001). After inhalation administration, the low-dose group, the medium-dose group, and the high-dose group were significantly reduced (P < 0.01), and there was a dose-dependency. The above results show that the Chinese medicine compound granules in Example 1 have a certain protective effect on the nasal mucosa of OVA-induced AR mice, and have a corresponding effect on reducing the infiltration of inflammatory cells (such as eosinophils and mast cells) in the nasal mucosa.
[0087] Figure 5V is HE (Hematoxylin-eosin, eosin staining) staining of lung tissue in order to evaluate the anti-inflammatory effect of the Chinese herbal compound granules of Example 1 on OVA-induced AR mice. Compared with the control group (Figure 5V-A), there were obvious histopathological changes in the lung tissue sections of OVA-induced AR mice (model group, Figure 5V-B), such as significant mucus production in the bronchial cavity, goblet cell hyperplasia in the bronchial epithelium, and inflammatory cell infiltration around blood vessels and bronchial areas. After the inhalation administration of the Chinese herbal compound granules of Example 1, it can be seen from Figures 5V-C, 5V-D, and 5V-E that the histopathological changes in the lung tissue were alleviated. These results show that the Chinese herbal compound granules of Example 1 have the effect of improving the inflammatory infiltration of the lung tissue of AR mice.
[0088] Fig. 6A -B is the effect of the Chinese medicine compound granules of Example 1 on the spleen index and thymus index of OVA-induced AR mice. The spleen index and thymus index are used to evaluate immune function. The spleen and thymus index of each group were calculated separately. It can be seen that the model group increased significantly, while the Chinese medicine compound granules of Example 1 showed a downward trend in each group, among which the low, medium and high dose groups of thymus index decreased significantly. It can be seen that the Chinese medicine compound granules of Example 1 have a certain regulatory effect on immune function.
[0089] As shown in Table 4 and Fig. 7A -D shows that the inflammation situation can be evaluated by the number and proportion of peripheral leukocytes: compared with the control group, the WBC (total white blood cell count) and Gran (eosinophils) in the model group were increased, while after the heated inhalation administration of the Chinese herbal compound granules in Example 1, the WBC (total white blood cell count), Lymph (peripheral blood lymphocytes) and Gran (eosinophils) were significantly reduced, and the changes were dose-dependent, but there was no significant difference in Mon (monocytes) between the groups, indicating that the Chinese herbal compound granules in Example 1 have a certain inhibitory effect on inflammatory cells (WBC, Gran and Lymph).
[0090] Table 4 The number of peripheral leukocytes and the proportion of each component in each group of mice (mean ± SD)
[0091]
[0092] As shown in Table 5-7, Fig. 8A -D. Fig.9A -B. Fig. 10A -B shows the test results of IFN-γ, IL-4, HIS, and OVA-slgE in each group of mice in this test example. From the test results of serum, NALF (nasal lavage fluid) and lung tissue homogenate related biochemical indicators, it can be seen that:
[0093] Compared with the model group, the inhalation group showed an increase in IFN-γ in serum and lung tissue homogenate, especially in the high-dose group, but there was no significant difference in IFN-γ in NALF.
[0094] Compared with the control group, the IL-4 levels in serum and NALF in the model group were increased, while those in the low, medium and high dose groups of inhalation administration were decreased.
[0095] Compared with the control group, the levels of HIS and OVA-slgE in serum of the model group were significantly increased, while those of the low, medium and high dose groups decreased after administration, especially the high dose group.
[0096] The above results indicate that the Chinese herbal compound granules of Example 1 can exert their effects by acting on inflammatory factors such as IFN-γ, IL-4, HIS and OVA-slgE.
[0097] Table 5 Results of mouse serum IFN-γ, IL-4, HIS, and OVA-slgE detection (means ± SD)
[0098]
[0099]
[0100] Table 6 IFN-γ and IL-4 detection results of nasal washing fluid (NALF) of mice in each group (means ± SD)
[0101] Group IFN-γ (pg / ml) IL-4 (pg / ml) Control 116.0±4.843 36.57±0.634 OVA 100.7±0.664 38.60±0.623 ZHW-L 107.1±5.509 35.32±1.777 ZHW-M 110.4±1.179 34.63±2.352* ZHW-H 141.2±32.820* 33.88±2.085* Budesonide 110.1±6.018 34.30±0.488*
[0102] Table 7 Detection results of IFN-γ and IL-4 in lung tissue of mice in each group (mean ± SD)
[0103] Group IFN-γ (pg / ml) IL-4 (pg / ml) Control 124.9±12.810 27.00±0.038 OVA 92.88±2.662# 37.20±3.618# ZHW-L 122.3±10.210 29.47±0.529* ZHW-M 139.1±2.986* 26.15±4.537** ZHW-H 142.3±16.401** 25.21±3.558** Budesonide 130.8±19.980* 26.04±1.855*
[0104] This test example explores the pharmacological effect of the inhalation treatment of AR by the Chinese herbal compound granules of Example 1 through in vivo animal experiments. First, KM female mice were randomly divided into a control group, a model group, a Chinese herbal compound inhalation administration group (low-dose group (ZHW-L), a medium-dose group (ZHW-M), a high-dose group (ZHW-H)) and a budesonide group. The dosage was determined by a preliminary experiment, and AR was sensitized by OVA stimulation, which was divided into two sensitization stages: basic sensitization and local sensitization, and the number of sneezing and runny nose within 20 minutes of the last local sensitization was used to determine whether the modeling was successful. On this basis, the pharmacological effect of the Chinese herbal compound granules in the treatment of AR in Example 1 was judged by analyzing the body weight, peripheral leukocyte count and ratio, spleen index, thymus index, serum and NALF-related biochemical indicators, nasal mucosa and lung tissue pathological section staining and the number of various inflammatory cells between the groups.
[0105] By comparing the staining of nasal mucosa and lung tissue pathological sections and the number of various inflammatory cells in each group, it can be seen that compared with the control group, the thickness of the mucosal layer and the number of inflammatory cells including eosinophils, goblet cells and mast cells in the OVA group were increased, and they were alleviated after inhalation administration, especially eosinophils and mast cells in the high-dose group under the compound inhalation administration treatment. There are significant differences, which shows that the Chinese medicine compound granules in Example 1 have a certain therapeutic effect on reducing inflammatory cells.
[0106] Therefore, the Chinese medicine compound granules of Example 1 have no toxicity to the weight and food intake of mice, and have a certain regulatory effect on immune function. The mechanism of action may be to exert a therapeutic effect by acting on inflammatory factors such as IFN-γ, IL-4, HIS and OVA-slgE in serum, but has nothing to do with IFN-γ and IL-4 in NALF. At the same time, it can reduce inflammatory cells such as eosinophils, goblet cells and mast cells in the nasal mucosa to relieve AR symptoms.
[0107] The embodiments of the present invention have been described above, and the above description is exemplary, not exhaustive, and is not limited to the disclosed embodiments. Many modifications and changes will be apparent to those skilled in the art without departing from the scope and spirit of the described embodiments.
Claims
1. A Chinese medicine compound granule, characterized in that: The Chinese medicine compound granules include a Chinese herbal medicine mixture, peppermint essential oil and a binder; The Chinese herbal medicine mixture includes Xanthium sibiricum, Magnolia officinalis, Angelica dahurica, Houttuynia cordata and Tangerine peel.
2. The Chinese medicine compound granules according to claim 1, wherein Based on the total weight of the traditional Chinese medicine compound granules, the traditional Chinese medicine compound granules comprise 67.5-78.5% of a Chinese herbal medicine mixture, 1.5-2.5% of peppermint essential oil and 20-30% of a binder.
3. The Chinese medicine compound granules according to claim 1 or 2, wherein: The mass ratio of the Xanthium sibiricum, Flos Magnolias, Angelica Dahuricae Dahuricae, Herba Houttuyniae and Pericarpium Citri Reticulatae is (1.5-2.5): (1.5-2.5): (2.5-3.5): (3.5-4.5): (3.5-4.5).
4. The Chinese medicine compound granules according to claim 1 or 2, wherein: The binder is at least one of glycerol, honey and CMC-Na solution.
5. The method for preparing the Chinese medicine compound granules according to any one of claims 1 to 4, characterized in that: The preparation method comprises the following steps: S1: uniformly mixing the peppermint essential oil and the adhesive to obtain an essential oil mixture; S2: uniformly mixing the Xanthium sibiricum, Magnolia officinalis, Angelica dahurica, Houttuynia cordata and Citrus reticulatae, and sequentially crushing and sieving to obtain a Chinese herbal medicine mixture; S3: uniformly mixing the essential oil mixture and the Chinese herbal medicine mixture, and sequentially subjecting the mixture to mixed granulation, primary sieving, drying, cooling and secondary sieving to obtain the Chinese herbal compound granules.
6. The method for preparing the Chinese medicine compound granules according to claim 5, wherein: In step S2, the mesh size of the sieving is 80-120 meshes.
7. The method for preparing the Chinese medicine compound granules according to claim 5, wherein: In step S3: The mesh size of the first screening is 22-26 mesh, and the mesh size of the second screening is 12-16 mesh; The drying temperature is 55-65°C and the drying time is 7.5-9 minutes.
8. Use of the Chinese medicinal compound granules according to any one of claims 1 to 4 as a drug for treating allergic rhinitis.
9. The use according to claim 8, wherein: The medicine for treating allergic rhinitis is administered by heating inhalation.
10. The use according to claim 9, wherein: The heating temperature is 250-270°C.
Citation Information
Patent Citations
Treatment method of acute / chronic nasosinusitis
CN105311110A
Nasal cavity cleaning fluid for treating allergic rhinitis
CN114288344A
Composition for preventing and treating rhinitis
CN118356452A
Medicine for treating rhinitis and its preparing process
CN1602906A
Therapeutic heater
CN2561427Y
